[A18-34] Dolutegravir/rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V
Last updated 17.09.2018
Commission awarded on 24.05.2018 by the Federal Joint Committee (G-BA).
Immune system and infections
HIV-1 infection in adults who are virologically-suppressed on a stable regimen for ≥ 6 months with no history of virological failure and no known or suspected resistance to any NNRTIs or INIs
Without indication for a treatment switch: indication of lesser benefit; with indication for a treatment switch: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.